New drug combo aims to stop precancerous blood disorder from turning deadly
NCT ID NCT02960555
Summary
This study is testing whether two drugs, isatuximab and lenalidomide, can delay or prevent high-risk smoldering multiple myeloma from progressing to active, symptomatic cancer. It involves 61 adults whose condition shows signs it is likely to worsen soon. Participants receive the drugs in cycles for up to 30 months to see if the treatment controls the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.